Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07622433 · ClinicalTrials.gov registry record · Phase 1
A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults
A Phase 1 study, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT07622433 is a Phase 1 study that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 18 participants.
The verdict
NCT07622433, a Phase 1 study, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to assess how well laroprovstat and ezetimibe combined in a single tablet to be taken by mouth works and what the body does to the drug (pharmacokinetics) compared with laroprovstat and ezetimibe individual tablets to be taken by mouth (relative bioavailability) as well as to see if there is any effect of eating compared to fasting (food effect) in healthy adults.
Interventions
- DRUG Laroprovstat/ezetimibe FCDP
- DRUG Laroprovstat STP
- DRUG Ezetimibe STP
- DRUG Laroprovstat/ezetimibe FCDP-slow variant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-06-10 |
| Est. Completion | 2026-09-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07622433
The ClinicalTrials.gov registry entry for NCT07622433 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laroprovstat/ezetimibe FCDP is the first listed.
NCT07622433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07622433 about?
NCT07622433 is a clinical study titled "A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults". The purpose of this study is to assess how well laroprovstat and ezetimibe combined in a single tablet to be taken by mouth works and what the body does to the drug (pharmacokinetics) compared with laroprovstat and ezetimibe individual tablets to be taken by mouth (relative bioavailability) as well ...
What is the current status of trial NCT07622433?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-06-10. Estimated completion is 2026-09-07.
What interventions are being tested in trial NCT07622433?
The interventions under investigation include: Laroprovstat/ezetimibe FCDP (DRUG), Laroprovstat STP (DRUG), Ezetimibe STP (DRUG), Laroprovstat/ezetimibe FCDP-slow variant (DRUG).
Who is sponsoring clinical trial NCT07622433?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.